Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Negative priming

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44300   clinical trials with a EudraCT protocol, of which   7354   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    27 result(s) found for: Negative priming. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2005-005849-19 Sponsor Protocol Number: RHM MED 0673 Start Date*: 2006-07-06
    Sponsor Name:Southampton University Hospitals NHS Trust
    Full Title: Finite duration treatment in pre-cirrhotic chronic hepatitis B virus (HBV) infection: Phase IV study of Lamivudine priming of Pegasys treatment in HBeAg positive patients
    Medical condition: pre-cirrhotic chronic hepatitis B virus (HBV) infection
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2008-005133-30 Sponsor Protocol Number: 810802 Start Date*: 2009-01-22
    Sponsor Name:Baxter Innovations GmbH
    Full Title: An Open Label Phase I/II Study to Assess the Immunogenicity and Safety of a Single Prime-Boost Vaccination Schedule with a Vero Cell-Derived Whole Virus H5N1 Influenza Vaccine in Healthy volunteers...
    Medical condition: H5N1 vaccination with a single Prime-Boost Vaccination schedule in healthy subjects aged 18 to 59 years.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10059430 Influenza immunization LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: AT (Completed) FI (Completed)
    Trial results: View results
    EudraCT Number: 2006-005477-22 Sponsor Protocol Number: 107495 Start Date*: 2007-01-22
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A phase II, open, randomized study in adults aged between 18 and 60 years designed to evaluate the reactogenicity and immunogenicity of a 1- and 2-dose prime-boost concept of pandemic monovalent (H...
    Medical condition: Immunization against influenza disease during pandemic in subjects aged 18 to 60 years.
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2007-000097-23 Sponsor Protocol Number: SAM109352 Start Date*: 2007-09-04
    Sponsor Name:GlaxoSmithKline
    Full Title: Rationale for therapy with low dose steroids combined with long-acting beta2-agonists in patients with allergic asthma: redirecting innate immune responses by long-term treatment with high doses of...
    Medical condition: Asthma
    Disease: Version SOC Term Classification Code Term Level
    9.1 10001705 Allergic asthma LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2018-001441-14 Sponsor Protocol Number: IFOM-CPT002/2018/PO001 Start Date*: 2018-10-29
    Sponsor Name:IFOM - Istituto FIRC di Oncologia Molecolare - Milano
    Full Title: PEMBROLIZUMAB IN MMR-PROFICIENT METASTATIC COLORECTAL CANCER PHARMACOLOGICALLY PRIMED TO TRIGGER DYNAMIC HYPERMUTATION STATUS
    Medical condition: RAS mutated metastatic colorectal cancer
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052358 Colorectal cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-000044-22 Sponsor Protocol Number: C1071005 Start Date*: 2021-09-14
    Sponsor Name:Pfizer Inc.
    Full Title: AN OPEN-LABEL, 3-ARM, MULTICENTER, RANDOMIZED PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ELRANATAMAB (PF-06863135) MONOTHERAPY AND ELRANATAMAB + DARATUMUMAB VERSUS DARATUMUMAB + POMALI...
    Medical condition: MULTIPLE MYELOMA
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Trial now transitioned) PL (Trial now transitioned) ES (Restarted) IT (Trial now transitioned) DE (Trial now transitioned) CZ (Trial now transitioned) NO (Trial now transitioned) FR (Trial now transitioned) FI (Trial now transitioned) NL (Trial now transitioned) BE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2007-000261-38 Sponsor Protocol Number: 108988 Start Date*: 2008-01-21
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A phase IV, open, multicentric study to evaluate the immune response to a hepatitis B challenge dose in healthy subjects, 72 to 78 months after they received a primary vaccination course of GSK Bio...
    Medical condition: Hepatitis B vaccine challenge dose given to subjects, 17 to 21 years of age, to evaluate immune memory to Hepatitis B antigen, approximately 6 years after priming with Hepatitis B vaccine.
    Disease:
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2010-018332-41 Sponsor Protocol Number: RibaC Start Date*: 2010-05-10
    Sponsor Name:Dept. of Infectious diseases / virology University of Gothenburg
    Full Title: A Randomized, Open-label, Parallel Group, Multicenter Pilot Study Evaluating the Efficacy and Safety of Alternative Dosing of Ribavirin vs. Standard of Care Dosing in Combination with Peginterferon...
    Medical condition: Chronic hepatitis C infection
    Disease: Version SOC Term Classification Code Term Level
    12.1 10008912 Chronic hepatitis C LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed) FI (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-001584-20 Sponsor Protocol Number: 207543 Start Date*: 2017-10-02
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A Phase I/II, randomized, controlled, observer-blind, multi-center study to assess the reactogenicity, safety and immunogenicity of three GlaxoSmithKline (GSK) Biologicals’ investigational supra-se...
    Medical condition: Healthy volunteers (active immunization for the prevention of disease caused by influenza virus)
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2012-004504-35 Sponsor Protocol Number: RF-2010-2311148 Start Date*: 2013-02-26
    Sponsor Name:IRCCS CENTRO SAN GIOVANNI DI DIO FATEBENEFRATELLI
    Full Title: The use of Oxytocin as adjunctive therapy for the treatment of schizophrenia: a randomized, double blind trial
    Medical condition: Schizophrenia
    Disease: Version SOC Term Classification Code Term Level
    14.1 10037175 - Psychiatric disorders 10039628 Schizophrenia and other psychotic disorders HLGT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2023-000944-46 Sponsor Protocol Number: 217218 Start Date*: 2024-05-31
    Sponsor Name:GLAXOSMITHKLINE BIOLOGICALS SA
    Full Title: A Phase IIa observer-blind, randomized, controlled, age-de-escalation, single center interventional study to evaluate the safety, reactogenicity, and immune response of the GVGH iNTS vaccine agains...
    Medical condition: Prevention of invasive nontyphoidal Salmonella disease
    Disease:
    Population Age: Infants and toddlers, Children, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: (No results available)
    EudraCT Number: 2006-003424-12 Sponsor Protocol Number: CD66-02 Start Date*: 2007-04-27
    Sponsor Name:University Hospital Southampton NHS Foundation Trust
    Full Title: A randomised phase II clinical trial using targeted radiotherapy delivered by an Yttrium-90 radiolabelled Anti-CD66 monoclonal antibody with high dose melphalan compared to melphalan alone, prior t...
    Medical condition: Multiple myeloma
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028228 Multiple myeloma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2022-001669-11 Sponsor Protocol Number: IFOM-CPT008/2022/PO007 Start Date*: 2022-09-22
    Sponsor Name:IFOM - Istituto FIRC di Oncologia Molecolare - Milano
    Full Title: Restoring sensitivity to immunotherapy in advanced triple negative breast cancer exploiting Ceralasertib priming followed by combined Durvalumab/Nab-paclitaxel: The ATRiBRAVE Trial.
    Medical condition: Unresectable locally advanced or metastatic triple-negative breast cancer
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004864 10006212 Breast carcinoma recurrent LLT
    20.1 100000004864 10006215 Breast carcinoma stage III LLT
    20.0 100000004864 10006216 Breast carcinoma stage IV LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-000142-34 Sponsor Protocol Number: ITCC-092/IST11028 Start Date*: 2020-09-15
    Sponsor Name:Princess Máxima Center for pediatric oncology
    Full Title: A Phase Ib study of Vyxeos® (liposomal daunorubicin and cytarabine) in combination with Clofarabine in children with relapsed/refractory AML, ITCC-092
    Medical condition: Relapsed or refractory pediatric acute myeloid leukemia
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10060558 Acute myeloid leukemia recurrent LLT
    21.1 100000004864 10081514 Acute myeloid leukemia refractory LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: NL (Trial now transitioned) AT (Trial now transitioned) DK (Trial now transitioned) IT (Trial now transitioned) DE (Trial now transitioned) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-005143-13 Sponsor Protocol Number: ONCOS-C719 Start Date*: 2016-05-06
    Sponsor Name:Targovax Oy
    Full Title: A randomised Phase II open-label study with a Phase Ib safety lead-in cohort of ONCOS-102, an immune-priming GM-CSF coding oncolytic adenovirus, and pemetrexed/cisplatin in patients with unresectab...
    Medical condition: Patients with unresectable malignant pleural mesothelioma
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004864 10049280 Solid tumour LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2007-000115-28 Sponsor Protocol Number: 109817 Start Date*: 2007-07-16
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A phase II, open, non-randomized study designed to evaluate the reactogenicity and immunogenicity of one or two booster administrations of an influenza pandemic candidate vaccine (GSK1562902A) in a...
    Medical condition: Since 1997, avian H5N1 influenza has caused several human infections and high mortality rate in Southeast Asia. Experts warn that the next influenza pandemic is imminent and could be severe. Preven...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2011-001448-31 Sponsor Protocol Number: H01_04E1TP Start Date*: 2011-09-12
    Sponsor Name:Novartis Vaccines Institute for Global Health (NVGH)
    Full Title: A Phase 2, open-label, single-center, extension study to evaluate the booster response induced by Vi-CRM197 after priming with either Vi-CRM197 or Typherix administered in adult subjects in H01_04T...
    Medical condition: Prophylaxis for Salmonella enterica serovar Typhi (S. Typhi) disease
    Disease: Version SOC Term Classification Code Term Level
    14.0 10021881 - Infections and infestations 10039446 Salmonella typhi infection LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2018-004353-24 Sponsor Protocol Number: LAMVYX Start Date*: 2019-11-04
    Sponsor Name:Fundación PETHEMA
    Full Title: A phase II, multicentre, open label clinical trial to assess the efficacy and toxicity of induction and consolidation with CPX-351 for patients aged 60 to 75 years with secondary or high-risk acute...
    Medical condition: Newly diagnosed secondary or high risk AML
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10000886 Acute myeloid leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-004287-26 Sponsor Protocol Number: 5F9009 Start Date*: 2021-05-19
    Sponsor Name:Gilead Sciences, Inc.
    Full Title: ENHANCE: A Randomized, Double-blind, Multicenter Study Comparing Magrolimab in Combination with Azacitidine versus Azacitidine Plus Placebo in Treatment-naïve Patients with Higher Risk Myelodysplas...
    Medical condition: Intermediate/high/very high risk myelodysplastic syndrome (MDS)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028533 Myelodysplastic syndrome PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) DE (Prematurely Ended) BE (Completed) IE (Prematurely Ended) NL (Completed) AT (Prematurely Ended) DK (Prematurely Ended) PT (Prematurely Ended) NO (Prematurely Ended) FI (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2012-002718-38 Sponsor Protocol Number: 111670 Start Date*: 2015-06-10
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A phase II, open, controlled, multi-center study to evaluate the long-term antibody persistence at 1 year, 3 years and 5 years after the administration of one dose of GlaxoSmithKline (GSK) Biologic...
    Medical condition: Invasive disease caused by Neisseria meningitidis serogroups A, C W-135 and Y
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004862 10028910 Neisseria meningitides meningitis LLT
    18.0 100000004862 10051931 Neisseria infection NOS LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA